LONGBIO-B (01779): Recommend adopting H-share stock purchase rights plan and H-share equity incentive plan.
Tianchen Biopharmaceuticals-B (01779) announced that on July 15, 2026, the board of directors has decided to recommend adopting the company's H-share subscription plan and H-share stock incentive plan.
LONGBIO-B (01779) announced that on July 15, 2026, the Board of Directors has proposed to adopt the company's H-share option scheme and H-share incentive scheme.
The H-share option scheme and H-share incentive scheme aim to establish and improve the company's long-term incentive mechanism, attract and retain key talents to drive business growth, and align the interests of shareholders, the company, and employees; commit to implementing a comprehensive strategy covering research and development, clinical development, and commercialization to promote the company's business transformation and value enhancement; promote cooperation to achieve a collaborative, shared, and win-win future; and promote the realization of the company's long-term strategic and performance goals. The share scheme is expected to provide the company with flexible means to retain, reward, compensate eligible individuals, and/or provide incentives to them.
The company's H-shares involved in the options granted under the H-share option scheme will be fulfilled by issuing and distributing new H-shares and/or transferring the company's treasury shares (if any). The H-shares involved in the share incentives granted under the H-share incentive scheme shall be purchased by the designated trustee through the following methods: (i) purchasing new H-shares from the company at face value; (ii) using the plan funds to purchase in the secondary market at the prevailing market price; and/or (iii) using the company's treasury shares (if any).
The maximum number of H-shares that can be issued and distributed or transferred from the treasury for all options and share incentives granted under the H-share option scheme and H-share incentive scheme, as well as for all options and share incentives granted under any other share scheme of the company, shall not exceed 10% of the total number of issued shares of the company on the day when the shareholders approve the scheme (excluding treasury shares, if any).
Related Articles

Tracking of Hong Kong stocks concepts | Intensive collaboration + Entry of industry giants, AI pharmaceutical commercialization enters fast lane (with concept stocks)

Geekplus-W (02590) spent 12.1131 million Hong Kong dollars to buy back 1.2 million shares on July 15.

China Sandi (00910): Pan Weigang appointed as executive director.
Tracking of Hong Kong stocks concepts | Intensive collaboration + Entry of industry giants, AI pharmaceutical commercialization enters fast lane (with concept stocks)

Geekplus-W (02590) spent 12.1131 million Hong Kong dollars to buy back 1.2 million shares on July 15.

China Sandi (00910): Pan Weigang appointed as executive director.

RECOMMEND





